Search
Indoramin
go.drugbank.com/drugs/DB08950ApprovedWithdrawnIndoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese.
International brands: BaratolGrape seed oil
go.drugbank.com/drugs/DB14323InvestigationalGrape seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: European Grape Seed OilPF-04937319
go.drugbank.com/drugs/DB15009InvestigationalPF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A176996] Its chemical structure contains a thieno[2,3-b][1,5]benzodiazepine core, and has a methyl group attached to the piperazine ring.
Products: Olanzapine Glenmark Europe(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigationalcompare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Tabirafusp tedromer
go.drugbank.com/drugs/DB19340InvestigationalTabirafusp tedromer is under investigation in clinical trial NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants
Synonyms: 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,4-hydroxy-N,N,N,10-tetramethyl-9-oxo-, inner salt, 4-oxide, homopolymer,9-arm star compd. with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxyOciperlimab
go.drugbank.com/drugs/DB18947InvestigationalOciperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage
Butriptyline
go.drugbank.com/drugs/DB09016ApprovedWithdrawnButriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.